Galie N. McLaughlin V.V. Rubin L.J. et al.

An overview of the 6th world symposium on pulmonary hypertension.

Eur Respir J. 53: 1802148Simonneau G. Montani D. Celermajer D.S. et al.

Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Eur Respir J. 53: 1801913Krowka M.J. Mandell M.S. Ramsay M.A. et al.

Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database.

Liver Transpl. 10: 174-182Kawut S. Krowka M.J. Trotter J.F. et al.

Clinical risk factors for portopulmonary hypertension.

Hepatology. 48: 196-203Krowka M.J. Fallon M.B. Kawut S.M. et al.

International liver transplant society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension.

Transplantation. 100: 1440-1452https://doi.org/10.1097/TP.0000000000001229DuBrock H.M. Goldberg D.S. Sussman N.L. et al.

Predictors of waitlist mortality in portopulmonary hypertension.

Transplantation. 101: 1609-1615Li J. Zhang Q. Zhang X. et al.

Prevalence and prognosis of portopulmonary hypertension in 223 liver transplant recipients.

Can Respir J. 2018: 9629570

Hepatopulmonary syndrome and portopulmonary hypertension: the pulmonary vascular enigmas of liver disease.

Clin Liver Dis. 15: S13-S24Berzigotti A. Seijo S. Reverter E. et al.

Assessing portal hypertension in liver diseases.

Expert Rev Gastroenterol Hepatol. 7: 141-155Bai W. Al-Karaghouli M. Stach J. et al.

Test-retest reliability and consistency of HVPG and impact on trial design: a study in 289 patients from 20 randomized controlled trials.

Hepatology. 74: 3301-3315Sithamparanathan S. Nair A. Thirugnanasothy L. et al.

Survival in portopulmonary hypertension: outcomes of the United Kingdom National Pulmonary Arterial Hypertension registry.

J Heart Lung Transpl. 36: 770-779Porres-Aguilar M. Altamirano J.T. Torre-Delgadillo A. et al.

Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview.

Eur Respir Rev. 21: 223-233

Portopulmonary hypertension.

Ann Thorac Med. 5: 5-9

Portopulmonary hypertension: diagnosis, clinical features, and medical therapy.

Clin Liver Dis. 4: 42-45Benjaminov F.S. Prentice M. Sniderman K.W. et al.

Portopulmonary hypertension in decompensated cirrhosis with refractory ascites.

Gut. 52: 1355-1362Pellicelli A.M. Barbaro G. Puoti C. et al.

Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation.

Angiology. 61: 802-806Reynaert H. Thompson M.G. Thomas T. et al.

Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Gut. 50: 571-581

Hepatic stellate cell activation and pro-fibrogenic signals.

J Hepatol. 67: 1104-1105Nikolic I. Yung L.M. Yang P. et al.

Bone morphogenic protein 9 is a mechanistic biomarker of portopulmonary hypertension.

Am J Respir Crit Care Med. 199: 891-902Rochon E.R. Krowka M.J. Bartolome S. et al.

BMP 9/10 in pulmonary vascular complications of liver disease.

Am J Respir Crit Care Med. 201: 1575-1578Breitkopf-Heinlein K. Meyer C. Konig C. et al.

BMP-9 interferes with liver regeneration and promotes liver fibrosis.

Gut. 66: 939-954DuBrock H.M. del Valle K.T. Krowka M.J.

Mending the MELD: an in-depth review of the past, present, and future of portopulmonary hypertension MELD exception.

Liver Transplant. https://doi.org/10.1002/lt.26422Kawut S.M. Taichman D.B. Ahya V.N. et al.

Hemodynamics and survival of patients with portopulmonary hypertension.

Liver Transpl. 11: 1107-1111Krowka M.J. Miller D.P. Barst R.J. et al.

Portopulmonary hypertension: a report from the US-based REVEAL registry.

Chest. 141: 906-915Salvador M.L. Loaiza C.A.Q. Padial L.R. et al.

Portopulmonary hypertension: prognosis and management in the current treatment era- results from the REHAP registry.

Intern Med J. 51: 355-365DuBrock H.M. Burger C.D. Bartolome S. et al.

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the pulmonary hypertension association registry.

Pulm Circ. 11 ()Goldberg D.S. Batra S. Sahay S. et al.

MELD exceptions for portopulmonary hypertension: current policy and future implementation.

Am J Transpl. 14: 2081-2087Aggarwal M. Li M. Bhardwaj A. et al.

Predictors of survival in portopulmonary hypertension: a 20-year experience.

Eur J Gastroenterol Hepatol. 34: 449-456Sahay S. Tsang Y. Flynn M. et al.

Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study.

Pulm Circ. 10 ()https://doi.org/10.1177/2045894020962917DuBrock H.M. Cartin-Ceba R. Channick R.N. et al.

Sex differences in portopulmonary hypertension.

Chest. 159: 328-336Al-Naamani N. Krowka M.J. Forde K.A.

Estrogen signaling and portopulmonary hypertension: the pulmonary vascular complications of liver disease study (PVCLD2).

Hepatology. 73: 726-737Roberts K.E. Fallon M.B. Krowka M.J. et al.

Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Am J Respir Crit Care Med. 179: 835-842Shao Y. Yin X. Qin T. et al.

Prevalence and associated factors of portopulmonary hypertension in patients with portal hypertension: a case-control study.

Biomed Res Int. : 5595614https://doi.org/10.1155/2021/5595614Sitbon O. Bosch J. Cottreel E. et al.

Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicenter, randomized, double-blind, placebo-controlled, phase 4 trial.

Lancet Respir Med. 7: 594-604Preston I.R. Burger C.D. Bartolome S. et al.

Ambrisentan in portopulmonary hypertension: a multicenter, open-label trial.

J Heart Lung Transpl. 39: 464-472Cartin-Ceba R. Swanson K. Iyer V. et al.

Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension.

Chest. 139: 109-114Hoeper M.M. Seyfarth H.J. Hoeffken G. et al.

Experience with inhaled iloprost and bosentan in portopulmonary hypertension.

Eur Respir J. 30: 1096-1102Hoeper M.M. Halank M. Marx C. et al.

Bosentan therapy for portopulmonary hypertension.

Eur Respir J. 25: 502-508Savale L. Magnier R. Le Pavec J. et al.

Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.

Eur Respir J. 41: 96-103Rossi R. Talarico M. Schepis F. et al.

Effects of sildenafil on right ventricular remodeling in portopulmonary hypertension.

Pulm Pharmacol Ther. 70: 102071https://doi.org/10.1016/j.pupt.2021.102071Reichenberger F. Vonswinckel R. Steveling E. et al.

Sildenafil treatment for portopulmonary hypertension.

Eur Respir J. 28: 563-567Fisher J.H. Johnson S.R. Chau C. et al.

Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.

Can Respir J. 22: 42-46Cartin-Ceba R. Halank M. Ghofrani H. et al.

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies.

Pulm Circ. 8 ()https://doi.org/10.1177/2045894018769305Kuo P.C. Johnson L.B. Plotkin J.S. et al.

Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension.

Transplantation. 63: 604-606Krowka M.J. Frantz R.P. McGoon M.D. et al.

Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

Hepatology. 30: 641-648Krowka M.J. Plevak D.J. Findlay J.Y. et al.

Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation.

Liver Transpl. 6: 443-450Freeman R.B. Gish R.G. Harper A. et al.

Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.

Liver Transpl. 12: S128-S136

Enhancements to the National liver review board, OPTN liver and intestinal organ transplantation committee.

() ()Salgia R.J. Goodrich N.P. Simpson H. et al.

Outcomes of liver transplantation for portopulmonary hypertension in model for end-stage liver disease era.

Dig Dis Sci. 59: 1976-1982Verma S. Hand F. Armstrong M.J. et al.

Portopulmonary hypertension: still an appropriate consideration for liver transplantation.

Liver Transpl. 22: 1637-1642Cartin-Ceba R. Burger C. Swanson K. et al.

Clinical outcomes after liver transplantation in patients with portopulmonary hypertension.

Transplantation. 105: 2283-2290DuBrock H.M. Runo J.R. Sadd C.J. et al.

Outcomes of liver transplantation in treated portopulmonary hypertension patients with a mean pulmonary arterial pressure ≥ 35mmHg.

Transpl Direct. 6: e630https://doi.org/10.1097/TXD.0000000000001085Jose A. Shah S.A. Anwar N. et al.

Pulmonary vascular resistance predicts mortality and graft failure in transplantation patients with portopulmonary hypertension.

Liver Transpl. 27: 1811-1823Cheng C. Wang Y. Wu T. et al.

Sildenafil monotherapy to treat portopulmonary hypertension before liver transplant.

Transpl Proc. 51: 1435-1438Sussman N. Kaza V. Barshes N. et al.

Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series.

Am J Transpl. 6: 2177-2182Ramsay M.A. Simpson B.R. Nguyen A.T. et al.

Severe pulmonary hypertension in liver transplant candidates.

Liver Transpl Surg. 3: 494-500Plotkin J.S. Kuo P.C. Rubin J. et al.

Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension.

Transplantation. 65: 457-459Koneru B. Ahmed S. Weisse A.B. et al.

Resolution of pulmonary hypertension of cirrhosis after liver transplantation.

Transplantation. 58: 1133-1135Hollatz T.J. Musat A. Westphal S. et al.

Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension.

Liver Transpl. 18: 686-695Savale L. Sattler C. Coilly A. et al.

Long-term outcome in liver transplantation candidates with portopulmonary hypertension.

Hepatology. 65: 1683-1692Koch D.G. Caplan M. Reuben A.

Pulmonary hypertension after liver transplantation: case presentation and review of the literature.

Liver Transpl. 15: 407-412Rafanan A.L. Maurer J. Mehta A.C. et al.

Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.

Chest. 118: 1497-1500

Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation.

Liver Transpl. 15: 15-19DuBrock H.M. Salgia R.J. Sussman N.L. et al.

Portopulmonary hypertension: a survey of practice patterns and provider attitudes.

Transpl Direct. 5: e456

Intraoperative anesthetic management of the liver transplant recipient with portopulmonary hypertension.

Curr Opin Organ Transpl. 24: 121-130Reddy K. Mallett S. Peachy T.

Venovenous bypass in orthotopic liver transplantation: time for a rethink?.

Liver Transpl. 11: 741-749

Anesthesia for liver transplant surgery.

Anesthesiol Clin North Am. 22: 687-711Paulsen A.W. Whitten C.W. Ramsay M.A. et al.

Considerations for anesthetic management during veno-venous bypass in adult hepatic transplantation.

Anesth Analg. 68: 489-496Rudnick M.R. De Marchi L. Plotkin J.S.

Hemodynamic monitoring during liver transplantation: a state of the art review.

World J Hepatol. 7: 1302-1311

Portopulmonary hypertension and right heart failure in patients with cirrhosis.

Curr Opin Anaesthesiol. 23: 145-150Ramsay M.A. Spikes C. East C.A. et al.

The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol.

Anesthesiology. 90: 299-301